S&P 500   3,271.88 (+0.78%)
DOW   26,954.22 (+0.52%)
QQQ   268.85 (+1.30%)
AAPL   110.70 (+2.29%)
MSFT   206.57 (+1.66%)
FB   250.96 (+0.57%)
GOOGL   1,428.00 (+0.36%)
AMZN   3,053.27 (+1.11%)
TSLA   401.24 (+3.47%)
NVDA   506.21 (+2.49%)
BABA   267.96 (-0.66%)
CGC   14.03 (-1.68%)
GE   6.07 (+0.17%)
MU   48.65 (-1.66%)
AMD   77.22 (+1.85%)
T   27.88 (-0.57%)
F   6.53 (-1.95%)
ACB   5.03 (-3.27%)
GILD   61.95 (-0.48%)
NFLX   476.31 (+0.68%)
DIS   122.63 (+0.11%)
BAC   23.34 (+0.00%)
BA   152.31 (+4.29%)
S&P 500   3,271.88 (+0.78%)
DOW   26,954.22 (+0.52%)
QQQ   268.85 (+1.30%)
AAPL   110.70 (+2.29%)
MSFT   206.57 (+1.66%)
FB   250.96 (+0.57%)
GOOGL   1,428.00 (+0.36%)
AMZN   3,053.27 (+1.11%)
TSLA   401.24 (+3.47%)
NVDA   506.21 (+2.49%)
BABA   267.96 (-0.66%)
CGC   14.03 (-1.68%)
GE   6.07 (+0.17%)
MU   48.65 (-1.66%)
AMD   77.22 (+1.85%)
T   27.88 (-0.57%)
F   6.53 (-1.95%)
ACB   5.03 (-3.27%)
GILD   61.95 (-0.48%)
NFLX   476.31 (+0.68%)
DIS   122.63 (+0.11%)
BAC   23.34 (+0.00%)
BA   152.31 (+4.29%)
S&P 500   3,271.88 (+0.78%)
DOW   26,954.22 (+0.52%)
QQQ   268.85 (+1.30%)
AAPL   110.70 (+2.29%)
MSFT   206.57 (+1.66%)
FB   250.96 (+0.57%)
GOOGL   1,428.00 (+0.36%)
AMZN   3,053.27 (+1.11%)
TSLA   401.24 (+3.47%)
NVDA   506.21 (+2.49%)
BABA   267.96 (-0.66%)
CGC   14.03 (-1.68%)
GE   6.07 (+0.17%)
MU   48.65 (-1.66%)
AMD   77.22 (+1.85%)
T   27.88 (-0.57%)
F   6.53 (-1.95%)
ACB   5.03 (-3.27%)
GILD   61.95 (-0.48%)
NFLX   476.31 (+0.68%)
DIS   122.63 (+0.11%)
BAC   23.34 (+0.00%)
BA   152.31 (+4.29%)
S&P 500   3,271.88 (+0.78%)
DOW   26,954.22 (+0.52%)
QQQ   268.85 (+1.30%)
AAPL   110.70 (+2.29%)
MSFT   206.57 (+1.66%)
FB   250.96 (+0.57%)
GOOGL   1,428.00 (+0.36%)
AMZN   3,053.27 (+1.11%)
TSLA   401.24 (+3.47%)
NVDA   506.21 (+2.49%)
BABA   267.96 (-0.66%)
CGC   14.03 (-1.68%)
GE   6.07 (+0.17%)
MU   48.65 (-1.66%)
AMD   77.22 (+1.85%)
T   27.88 (-0.57%)
F   6.53 (-1.95%)
ACB   5.03 (-3.27%)
GILD   61.95 (-0.48%)
NFLX   476.31 (+0.68%)
DIS   122.63 (+0.11%)
BAC   23.34 (+0.00%)
BA   152.31 (+4.29%)
Log in
NYSEAMERICAN:CRMD

CorMedix Stock Forecast, Price & News

$5.15
-0.08 (-1.53 %)
(As of 09/25/2020 01:00 PM ET)
Add
Compare
Today's Range
$5.13
Now: $5.15
$5.28
50-Day Range N/A
52-Week Range
$2.16
Now: $5.15
$7.97
Volume2,367 shs
Average Volume344,902 shs
Market Capitalization$160.88 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
Read More
CorMedix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CRMD
Previous SymbolNYSEMKT:CRMD
CUSIPN/A
Phone+1-908-5179500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees22
Market Cap$160.88 million
Next Earnings Date11/12/2020 (Estimated)
OptionableOptionable
$5.15
-0.08 (-1.53 %)
(As of 09/25/2020 01:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of CorMedix?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CorMedix
.

When is CorMedix's next earnings date?

CorMedix is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for CorMedix
.

How were CorMedix's earnings last quarter?

CorMedix Inc. (NYSEAMERICAN:CRMD) announced its quarterly earnings data on Monday, August, 10th. The biotechnology company reported ($0.14) EPS for the quarter, topping the Zacks' consensus estimate of ($0.24) by $0.10. The biotechnology company earned $0.02 million during the quarter, compared to the consensus estimate of $0.10 million.
View CorMedix's earnings history
.

When did CorMedix's stock split? How did CorMedix's stock split work?

CorMedix's stock reverse split before market open on Tuesday, March 26th 2019. The 1-5 reverse split was announced on Thursday, March 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 25th 2019. An investor that had 100 shares of CorMedix stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for CRMD?

3 brokers have issued 1-year price objectives for CorMedix's shares. Their forecasts range from $10.00 to $20.00. On average, they anticipate CorMedix's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 171.8% from the stock's current price.
View analysts' price targets for CorMedix
.

Are investors shorting CorMedix?

CorMedix saw a increase in short interest in the month of August. As of August 14th, there was short interest totaling 3,640,000 shares, an increase of 15.2% from the July 30th total of 3,160,000 shares. Based on an average daily trading volume, of 379,100 shares, the short-interest ratio is presently 9.6 days.
View CorMedix's Short Interest
.

Who are some of CorMedix's key competitors?

What other stocks do shareholders of CorMedix own?

Who are CorMedix's key executives?

CorMedix's management team includes the following people:
  • Mr. Khoso Baluch, CEO & Director (Age 61)
  • Mr. Robert W. Cook, Chief Financial Officer (Age 63)
  • Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 75)
  • Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 40)
  • Dr. Phoebe Mounts, Exec. VP & Gen. Counsel

What is CorMedix's stock symbol?

CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."

Who are CorMedix's major shareholders?

CorMedix's stock is owned by many different institutional and retail investors. Top institutional investors include Nuveen Asset Management LLC (0.39%), Steward Partners Investment Advisory LLC (0.31%), Charles Schwab Investment Management Inc. (0.20%), California Public Employees Retirement System (0.20%), Planning Directions Inc. (0.19%) and Bank of America Corp DE (0.09%). Company insiders that own CorMedix stock include Alan W Dunton, Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook and Steven W Lefkowitz.
View institutional ownership trends for CorMedix
.

Which institutional investors are selling CorMedix stock?

CRMD stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, and UBS Group AG.
View insider buying and selling activity for CorMedix
.

Which institutional investors are buying CorMedix stock?

CRMD stock was purchased by a variety of institutional investors in the last quarter, including Planning Directions Inc., California Public Employees Retirement System, SG Americas Securities LLC, Two Sigma Advisers LP, Bank of America Corp DE, Jacobs Levy Equity Management Inc., State Board of Administration of Florida Retirement System, and Avestar Capital LLC. Company insiders that have bought CorMedix stock in the last two years include Alan W Dunton, Hudson Executive Capital Lp, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Matthew T David, Mehmood Khan, Myron Kaplan, Phoebe Mounts, Robert W Cook, and Steven W Lefkowitz.
View insider buying and selling activity for CorMedix
.

How do I buy shares of CorMedix?

Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CorMedix's stock price today?

One share of CRMD stock can currently be purchased for approximately $5.15.

How big of a company is CorMedix?

CorMedix has a market capitalization of $160.88 million. CorMedix employs 22 workers across the globe.

What is CorMedix's official website?

The official website for CorMedix is www.cormedix.com.

How can I contact CorMedix?

CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.